Methadone

Ibogaine By David Dardashti Explains the Legal Status of Ibogaine

Retrieved on: 
Monday, March 25, 2024
Dardasht (Isfahan), Ibogaine, Darkness, Methadone, Risk, Substance abuse, Light, Research, Hope, Opioid, Pharmaceutical industry

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Ibogaine by David Dardashti is proud to announce more information about the legal status of ibogaine in Mexico and other countries for those recovering from an opiate addiction.

Key Points: 
  • MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Ibogaine by David Dardashti is proud to announce more information about the legal status of ibogaine in Mexico and other countries for those recovering from an opiate addiction.
  • Ibogaine Therapy Ibogaine is a revolutionary therapy which has been proven to reduce withdrawal symptoms and stop the cycle of substance abuse and opiate addiction in its tracks.
  • “It is our hope that through continued research those struggling with addiction can soon benefit from ibogaine without the fear of persecution or legal trouble,” said Gavriel Dardashti, Lead Scientific Researcher at Ibogaine By David Dardashti.
  • Ibogaine By david Dardashti continues to offer promises of hope despite drastic attempts of termination from those of greed and who lack a moral compass.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Pharmaceutical, Family, Consumer, Hospitals, Children, Science, Surgery, Baby, Maternity, Other Science, Health, JAMA Network Open, Ventricular septal defect, Risk, Infant, Prescription, MD, Methadone, MSHS, Hydromorphone, Morphine, Multimedia, Paper, Policy, Intubation, Fentanyl

View the full release here: https://www.businesswire.com/news/home/20240312681130/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312681130/en/
    In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location.
  • The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West.
  • “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says.
  • During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone.

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.

Sonara Health Partners with Oklahoma Treatment Services to Support Remote Methadone Dosing

Retrieved on: 
Wednesday, March 13, 2024
Partnership, Methadone, Patient, Opioid, Communication

TULSA, Okla., March 13, 2024 /PRNewswire/ -- As part of their mission to expand access to methadone take-home doses for patients in opioid treatment programs, Sonara Health has partnered with Oklahoma Treatment Services to make their application available to eligible patients.

Key Points: 
  • TULSA, Okla., March 13, 2024 /PRNewswire/ -- As part of their mission to expand access to methadone take-home doses for patients in opioid treatment programs, Sonara Health has partnered with Oklahoma Treatment Services to make their application available to eligible patients.
  • Oklahoma Treatment Services provides outpatient addiction treatment to more than 2,700 patients at seven locations across Oklahoma.
  • "We're teaming up with Sonara to revolutionize opioid addiction treatment, leveraging technology to break barriers and empower lives," said Oklahoma Treatment Services Executive Director Rod Cargill.
  • "The Oklahoma Treatment Services team is doing important, life-saving work, and we're thrilled to partner with them to make take-home methadone safer and more accessible," said Sonara Founder and CEO Michael Giles, MD.

Sonara Health Expands Remote Methadone Dosing Solution to Ohio Markets

Retrieved on: 
Monday, March 11, 2024
SAMHSA, Partnership, Health, Patient, Travel, MD, Methadone, Safety, CareSource

DAYTON, Ohio, March 11, 2024 /PRNewswire/ -- Sonara Health has partnered with BayMark Health Services — with funding from the nonprofit health plan CareSource — to make its remote dosing application available to eligible patients in Dayton and Amherst.

Key Points: 
  • DAYTON, Ohio, March 11, 2024 /PRNewswire/ -- Sonara Health has partnered with BayMark Health Services — with funding from the nonprofit health plan CareSource — to make its remote dosing application available to eligible patients in Dayton and Amherst.
  • This collaboration aims to change that, giving CareSource members access to Sonara's remote dosing technology as part of their opioid treatment program.
  • "CareSource is excited to partner with BayMark Health Services and Sonara Health.
  • This partnership will increase access to methadone take-home doses, decreasing daily travel and giving members more time in their day," said Stephanie Stitt, director, behavioral health at CareSource Ohio.

Year-End Impact Report Highlights Community Medical Services Successes in Community Engagement, Patient Outcomes and Expanding Access to Care

Retrieved on: 
Wednesday, January 31, 2024
Anxiety, Science, Research, Methadone, Social determinants of health, Suds, Patient, Naloxone, Counselor, CARF, Depression, Mental health, Opioid use disorder, SDOH, Acquisition, Mission, CMS, Accreditation, Health, OUD, Organization

The full impact report may be viewed and downloaded here .

Key Points: 
  • The full impact report may be viewed and downloaded here .
  • CMS approaches patient care with a clear and unique Vision: Leading the change to eliminate the consequences of substance use disorder in our communities.
  • Community Medical Services remains dedicated to providing evidence-based care to actively address the complex challenges associated with opioid use disorder.
  • * Analysis from SDOH assessments conducted by medical providers at every visit, for every patient being treated with methadone from May 2022-June 2023.

Remote Methadone Dosing Solution Sonara Health Expands into Alaska with SEARHC Partnership

Retrieved on: 
Tuesday, January 23, 2024
Patient, MD, Health, Partnership, Opioid use disorder, Methadone, Addiction medicine, Pharmaceutical industry

JUNEAU, Alaska, Jan. 23, 2024 /PRNewswire/ -- Sonara Health has partnered with SouthEast Alaska Regional Health Consortium to make it easier for patients to access life-saving methadone treatment through Sonara's remote dosing application.

Key Points: 
  • JUNEAU, Alaska, Jan. 23, 2024 /PRNewswire/ -- Sonara Health has partnered with SouthEast Alaska Regional Health Consortium to make it easier for patients to access life-saving methadone treatment through Sonara's remote dosing application.
  • This partnership marks Sonara's first expansion into Alaska, where their solution will be available to eligible patients at clinics in Klawock, Sitka and Juneau.
  • SEARHC provides a wide variety of services to 27 communities in Southeast Alaska, including methadone treatment for Opioid Use Disorder.
  • With Sonara's web-based application, SEARHC patients will be able to record their methadone doses for their care teams to review.

Ibogaine By David Dardashti Analyzes Connections Between Physical and Emotional Pain

Retrieved on: 
Monday, January 15, 2024
Hydrocodone, Oxycodone, Fentanyl, Physical fitness, Communication, Opioid, Chronic pain, Ibogaine, Pain, Methadone, Buprenorphine/naloxone, Research, Brain, Nursing

While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.

Key Points: 
  • While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.
  • Research suggests that opiates enhance the production of opiate receptors, creating interconnected pathways that regulate both physical and emotional pain.
  • These drugs create interconnected pathways that regulate both emotional and physical pain, providing relief to individuals struggling with opioid addiction.
  • This not only helps individuals recover without having to undergo physical and emotional discomfort, but also stabilizes the brain and body, improving communication between physical and emotional pain.